autologous skeletal myoblast therapy (ACTC)

N/A

Report date: 2025/03/14 20:00:48

Base Information

Drug Nameautologous skeletal myoblast therapy (ACTC)
Drug Alias Nameautologous skeletal myoblast therapy (Advanced Cell Technology)autologous skeletal myoblast therapy (Terumo)autologous stem cell therapy (Terumo)autologous stem cell therapy (Mytogen)autologous skeletal myoblast therapy (Mytogen) +[6] 
ClassificationCell and gene therapy > Cell therapy > Stem cell therapy > Myogenic potential stem cell therapy
Mechanisms of ActionUpdating
TargetsUpdating
Therapy Area/IndicationsHeart Failure
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited StatesJapan
CombinationsNo
Global Highest StatusDiscontinued (Phase 1 Clinical)
Highest Status in ChinaN/A
Originator CompaniesMytogen Inc
China Registration ClassN/A

Develop Information

Active CompaniesN/A
Inactive CompaniesMytogen IncAstellas Institute For Regenerative MedicineTerumo Corp
Active IndicationsN/A
Inactive IndicationsHeart Failure

Other Information

ATC CodeN/A
Related LinksN/A